(RTTNews) - Corvus Pharmaceuticals Inc. (CRVS) said Tuesday that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. Corvus is studying an agonistic humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer. In both in vitro and in vivo studies in cancer patients, CPI-006 has demonstrated binding to various immune cells and the inducement of a humoral adaptive immune response - B cell activation and lymphocyte trafficking leading to the production of antigen-specific immunoglobulin (IgM and IgG) antibodies.